Locations:
Search
Interim results of RUBY study also indicate improved physical function and quality of life
Efficacy, safety and tolerability data shared at hematology meeting
How to combat the rise in mortality when patients become adults
Two-year event-free survival comparable to matched sibling donor myeloablative transplant
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
First-in-human trials of CRISPR-Cas12a gene editing demonstrate safety and meaningful event-free survival
First in-human trial using CRISPR/CASP 12 for gene editing in sickle cell disease
A 12-year-old patient and others in clinical trial are cured of sickle cell disease thanks to half-match donors
A primary care update
Disease-modifying medications, haploidentical transplant and gene therapies
Treating sickle cell disease sometimes takes a village
Advertisement
Advertisement